GC Famliy Site

cookie-layer close

COOKIE Setting

When you visit our website, information is stored in your browser or exported in the form of cookies.This information may be about you, your preferences, or the device you use, and is most often used to ensure that the website works properly. This information does not identify you directly, but it can offer a more optimized experience as you navigate our website. Because we respect your right to privacy, you may choose not to allow certain types of cookies. You can check the detailed settings and change them according to your needs.
Analytical cookies

These cookies collect information about how visitors use the website to help improve the site. For example, we anonymously collect information such as the visitor’s device, access area, and time of visit.

  • - Google Analytics (GA4)

    Lorem ipsum dolor sit amet consectetur adipisicing elitsumenda quia nesciunt quo aut soluta. Ipsa qui dolore minima odio facere?

img

Pipeline

R&D Pipeline
img

One More Step for Future
Cell Therapy R&D

R&D Highlights

  • HER2 Allogeneic CAR-NK cell therapy

  • NK/T cell therapy platform technology overcoming existing challenges

  • Potential first-in-class or best-in-class addressing unmet needs

  • Expanded indication of Immuncell-LC

Classification Project Research Preclinical Phase 1 Phase 2 Phase 3 BLA
Allogeneic GCC4001
(AB-101,
Naive NK Cell)
+ Rituximab
r/r* Lymphoma
Ph1 on-going
GCC4001
(AB-101,
Naive NK Cell)
+ Rituximab
Lupus (Autoimmune)
US FDA IND cleared
GCC4001
(AB-101,
Naive NK Cell)
+ AFM13
r/r* Hodgkin Lymphoma / CD
Ph2 cleared by US FDA (May, ‘23)
GCC2003
(AB-201,
HER2 CAR-NK)
HER2+ Solid Cancer
Multi-regional study; IND cleared by US FDA; IND cleared in Australia and Korea
GCC2004
(AB-202,
CD19 CAR-NK)
B-cell Lymphoma
GCC2005
(AB-205,
CD5 CAR-NK)
T-cell Lymphoma
Autologous GCC4002
(Immuncell-LC,
CIK**)
Pancreatic Cancer Ph3 on-going
GCC4002
(Immuncell-LC,
CIK**)
Liver cancer(HCC) Approved in Korea
* r/r : Relapsed/Refractory
** CIK, cytokine-induced killer cell

GC Cell NK Competitiveness

img
  • img

    Efficacy

    Kill tumor cells without the need for prior activation

  • img

    Accessibility

    Cryopreserved and Ready to Infusion product

    No time delay which is unacceptable for many patients with rapidly growing cancers

  • img

    Affordable

    Scales of production lowers treatment cost significantly

  • img

    Safety

    Unlike approved CAR-T therapy or T cell engagers require hospitalization and extended monitoring, NK cells are available in outpatient setting

  • img

    Flexible treatment for each individual patient

    NK cells can be combined with mAb or engager for multi-targeting approaches

    NK cells can be used in repeat dosing regimen at any given time during the course of treatment

CBNK (Cord blood-derived NK)

GC Cell CBNK(AB-101) is a non-engineered, cryopreserved [1]allogeneic off-the-shelf drug developed on outstanding cell expansion and manufacturing platform using GC Cell proprietary feeder system. The exclusive engineered feeder cell eHut78 enables optimal NK cell expansion and potent antitumor activity. [2]Our advanced technology provides mass production of AB-101 in a scale of up to 5,000 doses from a single cord blood unit maintaining high NK cell quality.

  • 01
    Isolation

    CD3 Depletion

    img

    Immature Cord Blood
    NK Cells

  • 02
    Activation & Expansion #1

    Bag Culture

    img
  • 03
    Master Cell Bank

    Cryostorage
    ±80 bags @ 108 cells/bag

    img img img
  • 04
    Activation & Expansion #2

    50L Bioreactor

    img
  • 05
    Drug Product

    Cryostorage
    5,000’s of Doses/Cord

    img
Gene Engineered-CBNK

GC Cell Gene-engineered NK cells that express chimeric antigen receptor (CAR) show enhanced targeting to the hematologic and solid tumors. The GC Cell proprietary CAR platform is optimized to maximize the therapeutic effects of NK cells. Our CAR platform utilizes CD28 and OX40L costimulatory molecules to amplify activating signals and is armored with secreting IL-15 cytokine to increase NK cell persistency. [3][4]

  • [1]MEDIUM COMPOSITION FOR CRYOPRESERVATION OF CELL AND USE THEREOF (PCT/KR2017/000859)
  • [2]METHOD FOR CULTURING CORD BLOOD-DERIVED NATURAL KILLER CELLS USING TRANSFORMED T-CELLS (PCT/KR2019/015469)
  • [3]CHIMERIC ANTIGEN RECEPTOR AND NATURAL KILLER CELLS EXPRESSING SAME (PCT/KR2017/015635)
  • [4]FUSION PROTEINS COMPRISING CHIMERIC ANTIGEN RECEPTORS AND IL-15 (PCT/KR2022/095077)